Condition: Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 · Sponsor: Boehringer Ingelheim
This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of obrixtamig and the best treatment schedule that people can tolerate. Obrixtamig is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, obrixtamig is given to people for the first time. Interim clinical data are available for obrixtamig. Participants get obrixtamig either weekly or once every 3 weeks. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about 20 times depending on the response to the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| University of Maryland School of Medicine | Baltimore, Maryland, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Completed |
| Universitätsklinikum Köln (AöR) | Cologne, Germany | Completed |
| Technische Universität Dresden | Dresden, Germany | Recruiting |
| Universitätsklinikum Würzburg AÖR | Würzburg, Germany | Recruiting |
| National Cancer Center Hospital East | Chiba, Kashiwa, Japan | Recruiting |
| Hospital del Mar | Barcelona, Spain | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Recruiting |
| Clínica Universidad de Navarra | Pamplona, Spain | Recruiting |
| Hospital Clinico Universitario de Valencia | Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04429087